Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Collagenase With Antibiotic Ointment of Minor Partial Thickness Burns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information. For subjects not able to provide informed consent (e.g., minors), a parent or legally authorized representative must provide consent. Assent must be provided as required by the Institutional Review Board (IRB).~2. Have one or more acute burns which:~   1. are thermal, chemical or electrical in etiology~  2. in aggregate cover \<10% total body surface area (TBSA)~  3. are each equal to or less than 72 hrs old~  4. are each no more than deep partial thickness (2nd degree)~  5. are not visibly infected~3. Able to take in oral fluids.~4. Able to comply with the requirement for daily dressing changes, or have a caretaker who is able to comply.~5. Willing to make all required study visits.~Exclusion Criteria:~1. Contraindications or hypersensitivity to the use of the test article or their components (e.g., known hypersensitivity to bacitracin).~2. Embedded foreign bodies in the burn wound which cannot be immediately removed.~3. The burned tissue includes or is within 1 cm of the eye or genitalia.~4. Severe perioral burns.~5. Airway involvement or aspiration of hot liquids.~6. Suspicion of physical abuse.~7. Burn wound requires a skin graft.~8. Outpatient management of the burn wound is not appropriate.~9. Participation in another investigational clinical study within thirty (30) days of the Screening Visit.~10. The Investigator may declare any subject ineligible for a valid medical reason. Current or recent (\< 6 months) history of severe, unstable, or uncontrolled neurological, cardiovascular, gastrointestinal, hematological, hepatic, and/or renal disease or evidence of other diseases based upon a review of medical history that, in the opinion of the Investigator, would preclude safe subject participation in the study.~11. Test articles are cost-prohibitive for subjects

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Collagenase Santyl (Type: ACTIVE_COMPARATOR): Applied topically (2 mm thickness once daily)
- Bacitracin (Type: SHAM_COMPARATOR): Applied topically (2 mm thickness) once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).